Genealogist Bernice Bennett hosts Alnylam's newest hATTR amyloidosis awareness campaign (Alnylam)

Al­ny­lam takes a fam­i­ly road trip to talk about health his­to­ry and hered­i­ty in new rare dis­ease cam­paign

Al­ny­lam Phar­ma­ceu­ti­cals is hit­ting the road with a ge­neal­o­gist and health ed­u­ca­tor in its lat­est dig­i­tal cam­paign around hered­i­tary AT­TR (hAT­TR) amy­loi­do­sis. The host, ge­neal­o­gist Ber­nice Ben­nett, leads the crew around the coun­try to talk to a physi­cian ex­pert along with fam­i­lies af­fect­ed by the rare ge­net­ic con­di­tion to dis­cuss their ex­pe­ri­ences, and some­times dif­fi­cult fam­i­ly con­ver­sa­tions.

hAT­TR amy­loi­do­sis is an au­to­so­mal dom­i­nant dis­ease, mean­ing each child with a par­ent who has the ge­net­ic vari­ant has a 50% chance of in­her­it­ing it. An es­ti­mat­ed 50,000 peo­ple in the world have hAT­TR — in­clud­ing about 10,000 to 15,000 peo­ple in the US — but some 35,000 re­main un­di­ag­nosed.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.